Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Discovery and characterization of ACT-451840 : an antimalarial drug with a novel mechanism of action
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 3645710
Author(s) Boss, Christoph; Aissaoui, Hamed; Amaral, Nathalie; Bauer, Aude; Bazire, Stephanie; Binkert, Christoph; Brun, Reto; Bürki, Cédric; Ciana, Claire-Lise; Corminboeuf, Olivier; Delahaye, Stephane; Dollinger, Claire; Fischli, Christoph; Fischli, Walter; Flock, Alexandre; Frantz, Marie-Céline; Girault, Malory; Grisostomi, Corinna; Friedli, Astrid; Heidmann, Bibia; Hinder, Claire; Jacob, Gael; Le Bihan, Amelie; Malrieu, Sophie; Mamzed, Saskia; Merot, Aurelien; Meyer, Solange; Peixoto, Sabrina; Petit, Nolwenn; Siegrist, Romain; Trollux, Julien; Weller, Thomas; Wittlin, Sergio
Author(s) at UniBasel Brun, Reto
Wittlin, Sergio
Year 2016
Title Discovery and characterization of ACT-451840 : an antimalarial drug with a novel mechanism of action
Journal ChemMedChem
Volume 11
Number 18
Pages / Article-Number 1995-2014
Abstract More than 40 % of the world's population is at risk of being infected with malaria. Most malaria cases occur in the countries of sub-Saharan Africa, Central and South America, and Asia. Resistance to standard therapy, including artemisinin combinations, is increasing. There is an urgent need for novel antimalarials with new mechanisms of action. In a phenotypic screen, we identified a series of phenylalanine-based compounds that exhibit antimalarial activity via a new and yet unknown mechanism of action. Our optimization efforts culminated in the selection of ACT-451840 [(S,E)-N-(4-(4-acetylpiperazin-1-yl)benzyl)-3-(4-(tert-butyl)phenyl)-N-(1-(4-(4-cyanobenzyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)acrylamide] for clinical development. Herein we describe our optimization efforts from the screening hit to the potential drug candidate with respect to antiparasitic activity, drug metabolism and pharmacokinetics (DMPK) properties, and in vivo pharmacological efficacy.
Publisher WILEY-V C H VERLAG GMBH
ISSN/ISBN 1860-7179
edoc-URL http://edoc.unibas.ch/44584/
Full Text on edoc No
Digital Object Identifier DOI 10.1002/cmdc.201600298
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/27471138
ISI-Number WOS:000383693800005
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.394 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
03/05/2024